Blaise Lippa

Blaise Lippa, PhD is Head of Chemistry at Morphic Therapeutic Inc. He was employee number two at the company, and a part of the initial company formation in June 2015. Prior to this, Blaise was a Senior Director of Medicinal Chemistry at Cubist Pharmaceuticals from 2008 to 2015, with a focus on antibacterials, pain and Inflammatory Bowel Disease (IBD). At Cubist, he led teams that advanced multiple compounds to the clinic, and served on a development team that achieved an NDA prior to the purchase of the company by Merck. Blaise began his career in medicinal chemistry at Pfizer in 1999. He conducted advanced drug design in multiple therapeutic indications, including oncology, antibacterials and metabolic diseases. At Pfizer, Blaise was successful in advancing multiple compounds to clinical study, including an oncology therapy currently in a phase 2 trial. Blaise obtained dual B.Sc. degrees in chemistry and molecular biology from the University of Michigan at Ann Arbor in 1995, and his Ph.D. from Stanford University in 1999 while working with Professor Paul Wender. Blaise is an author of over 60 publications and patents.